Business Standard

Monday, December 23, 2024 | 11:52 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Cipla to collaborate with US-based MEDRx for muscle relaxant drug

As per the deal, MEDRx to receive upfront payment of about $ 30 mn & will be eligible for royalties

Cipla to collaborate with US-based MEDRx for muscle relaxant drug
Premium

BS B2B Bureau Mumbai
Cipla USA Inc, the wholly-owned subsidiary of the Mumbai-based pharmaceutical company Cipla, has signed a worldwide licensing agreement (except for East Asia) with MEDRx Company Limited (MEDRx) to further develop and commercialise MRX-4TZT, a tizanidine patch for the management of Spasticity. Tizanidine is a type of central analgesic (acts on the central nerves in the brain and the spinal cord to relieve muscle tonicity). This drug is used to alleviate discomfort from shoulder stiffness, back problems, frozen shoulder, tension headaches and other problems.

Under the terms of the agreement, MEDRx is eligible to receive up to $ 30 million cumulatively through

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in